Clinical Report: OMNI Ultra Makes AAO Debut

Overview

Sight Sciences announced commercial availability of the OMNI Ultra Surgical System ahead of its demonstration at the 2026 American Academy of Ophthalmology Annual Meeting. The implant-free system combines single-pass canaloplasty with subsequent trabeculotomy and is designed to reduce intraocular pressure in adults with primary open-angle glaucoma.

Background

Primary open-angle glaucoma is the indicated condition for OMNI Ultra, which received FDA 510(k) clearance for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adults with the disease. The system builds on the existing OMNI platform and targets the trabecular meshwork, Schlemm's canal, and collector channels in the conventional aqueous outflow pathway. The European Glaucoma Society's 6th Edition guidelines classify OMNI among trabecular surgeries involving viscodilation and trabecular disruption, and describe MIGS as used mainly to reduce IOP and/or medication burden in early-to-moderate open-angle disease. The supplied guideline context states that MIGS may be performed with cataract surgery or as a standalone procedure, with surgical choice individualized to disease severity and target pressure.

Data Highlights

Key Findings

• Sight Sciences announced commercial availability of OMNI Ultra before its debut at the 2026 AAO Annual Meeting.
• The device performs canaloplasty around the circumference of Schlemm's canal in a single pass, followed by trabeculotomy.
• The system is designed to address resistance associated with the trabecular meshwork, Schlemm's canal, and collector channels.
• TruSync Plus automatically delivers viscoelastic during both advancement and retraction of the microcatheter; enhanced catheter visualization is intended to provide greater visibility and control.
• OMNI Ultra can be used as a standalone procedure or with cataract surgery and, like earlier OMNI versions, leaves no implant in the eye.
• The FDA granted 510(k) clearance for canaloplasty followed by trabeculotomy to reduce IOP in adults with POAG, according to the related Glaucoma Physician report.

Clinical Implications

The reported indication and procedural options describe OMNI Ultra as an implant-free MIGS system for adults with POAG, usable alone or with cataract surgery. The supplied EGS guideline context states that MIGS selection should be individualized according to disease severity and target pressure, and that these procedures are generally not indicated for advanced glaucoma or angle-closure disease.

Conclusion

OMNI Ultra adds automated viscoelastic delivery and enhanced catheter visualization to the OMNI platform's canaloplasty-and-trabeculotomy approach. Sight Sciences planned demonstrations at AAO 2026 following the system's commercial launch and FDA clearance.

Related Resources & Content

1. Glaucoma Physician, 2026 — FDA Clears Omni Ultra for POAG
2. Optometric Management, 2026 — Sight Sciences Announces Commercial Availability of Omni Ultra Surgical System
3. Ophthalmology Management, 2026 — Sight Sciences to Debut the Omni Ultra Surgical System at AAO 2026
4. American Academy of Ophthalmology, 2026 — Primary Open-Angle Glaucoma Preferred Practice Pattern
5. Glaucoma Physician — Sight Sciences Launches Omni Ultra Surgical System Recommendations
6. FDA Clears Omni Ultra for POAG
7. Sight Sciences Announces Commercial Availability of Omni Ultra Surgical System
8. Sight Sciences to Debut the Omni Ultra Surgical System at AAO 2026
9. Primary Open-Angle Glaucoma Preferred Practice Pattern
10. Canaloplasty and Trabeculotomy Combined with Phacoemulsification for Glaucoma: 12-Month Results of the GEMINI Study - PMC
11. https://sage.cnpereading.com/doi/10.1177/11206721251376889?utm_source=openai